Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610626 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2019.04.015 | DOI Listing |
Publication Analysis
Top Keywords
imiquimod-induced effluvium
4
effluvium intravaginal
4
intravaginal application
4
application treatment
4
treatment cervical
4
cervical intraepithelial
4
intraepithelial neoplasia
4
imiquimod-induced
1
intravaginal
1
application
1
Similar Publications
Imiquimod-induced effluvium after intravaginal application for treatment of cervical intraepithelial neoplasia.
JAAD Case Rep
July 2019
University Department of Dermatology, Medical University of Vienna, Vienna, Austria.
A case of imiquimod-induced alopecia.
J Dermatolog Treat
March 2010
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1071, USA.
Imiquimod cream 5% is an immune modifier approved for the treatment of genital warts, actinic keratosis, and basal cell carcinoma. This case report presents an isolated case of telogen effluvium after 6 weeks of imiquimod treatment for an actinic keratosis on the scalp. Based on this case presentation, telogen effluvium is a potential rare side effect from imiquimod treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!